Free Newsletter
LRPR1: A new target for obesity, diabetes
Researchers at the University of Cincinnati have identified a new target for drug developers out to control obesity and diabetes. David Hui, PhD, and colleagues say that they knocked out adipocyte low density lipoprotein receptor-related protein 1, or LRPR1, cell receptors in mice and registered a dramatic physical response. The knockout mice stored less fat and gained less weight while expending more energy than control mice. A separate group of researchers at UT Southwestern Medical Center undertook the same experiment and duplicated the results, confirming the promise of this approach.
"Our study has shown this molecule directly impacts the rate of fat transport in the body, so with further study it could be a new target for drugs aimed at controlling obesity," says Hui.
"This shows that LRPR1 is a critical regulator of lipid absorption in fat cells," said Susana Hoffman, a pathology research professor at UC and a member of Hui's team. "Preventing these interactions in our model prevented the onset of obesity and diabetes."
- check out the release on the study
- here's the UPI report
Related Articles:
Common virus is a culprit in obesity. Report
Molecular research points to new obesity therapy. Report
Scripps researchers find anti-obesity vaccine. Report
Enzyme discovery offers new direction in diabetes. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: